Development of a biomarker for predicting the clinical effectiveness of tezepelumab in patients with severe asthma and elucidation of immunomodulatory effects of tezepelumab
Not Applicable
- Conditions
- bronchial asthma
- Registration Number
- JPRN-UMIN000052764
- Lead Sponsor
- Juntendo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Subjects with malignancy Current smokers and subjects with a history of smoking within the past 6 months Subjects receiving treatment with other biologics and less than 1 month since last administraion (benralizumab requires 2 months) Subjects who have received bronchial thermoplasty within the past 6 months Subjects with a history of anaphylaxis due to biologics Subjects currently pregnant or breastfeeding Subjects with chronic obstructive pulmonary disease with obvious emphysematous changes Subjects with hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, pulmonary hypertension, sequelae of tuberculosis, diffuse panbronchiolitis, and interstitial pneumonia
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method